Palleschi, M., Gianni, C., Merloni, F., Farolfi, A., Miserocchi, G., Gentili, N., Mariotti, M., Menna, G. D., Serra, O., Casadei, C., Rusconi, F., Andalò, A., Sabbioni, S., Carlini, A., Montanari, D., Sirico, M., Maltoni, R., Cecconetto, L., Sarti, S., Musolino, A. (2026). Real-world survival benefit of glucagon-like peptide-1 receptor agonists (GLP-1 Ras) concomitant with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and endocrine therapy in hormone receptor-positive (HR+)/HER2− metastatic breast cancer: A large propensity-matched analysis.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.1070